The purpose of this study is to compare galeterone to enzalutamide in men expressing androgen receptor spice variant-7 mRNA (AR-V7) in metastatic (M1) castrate resistant prostate cancer (CRPC).
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
953
2550 mg galeterone tablets once daily PO
160 mg enzalutamide capsules once daily PO
Radiographic Progression-free survival
Time frame: ≥ 8 months
Overall Survival
Time frame: ≥ 8 months
Time to Initiation of Cytotoxic Chemotherapy
Time frame: ≥ 8 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Pinnacle Oncology Hematology
Scottsdale, Arizona, United States
University Of Arizona Cancer Center
Tucson, Arizona, United States
City of Hope
Duarte, California, United States
USC Norris Comprehensive Cancer Center
Los Angeles, California, United States
UCLA Jonsson Comprehensive Cancer Center
Los Angeles, California, United States
Prostate Oncology Specialists, Inc.
Marina del Rey, California, United States
UC Davis Cancer Center
Sacramento, California, United States
San Bernardino Urological Associates
San Bernardino, California, United States
Urology Speciality Group
Torrance, California, United States
University of Colorado Cancer Center Anschultz Cancer Pavilion
Aurora, Colorado, United States
...and 107 more locations